Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients

Clinical trial NCT02187367 · TERMINATED

Trial details

NCT number: NCT02187367
Sponsor: Bioven Europe
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2015-05-01
Primary completion: 2019-05-01
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.